Search Results - "CIRINCIONE, B"

The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases by Davis, Sarah E, Cirincione, Abagail B, Jimenez-Torres, Ana Catya, Zhu, Jun

“…Neurodegenerative diseases affect millions of people worldwide. Neurodegenerative diseases result from progressive damage to nerve cells in the brain or…”
Get full text

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections by PASSARELL, J. A, MEAGHER, A. K, LIOLIOS, K, CIRINCIONE, B. B, VAN WART, S. A, BABINCHAK, T, ELLIS-GROSSE, E. J, AMBROSE, P. G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections by MEAGHER, A. K, PASSARELL, J. A, CIRINCIONE, B. B, VAN WART, S. A, LIOLIOS, K, BABINCHAK, T, ELLIS-GROSSE, E. J, AMBROSE, P. G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

GLP-1 based therapies: differential effects on fasting and postprandial glucose by Fineman, M.S., Cirincione, B.B., Maggs, D., Diamant, M.

“…Glucagon‐like peptide‐1 (GLP‐1), a gut‐derived hormone secreted in response to nutrients, has several glucose and weight regulating actions including…”
Get full text

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment by Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., Trautmann, M. E.

“…Aims: Antibody formation to therapeutic peptides is common. This analysis characterizes the time‐course and cross‐reactivity of anti‐exenatide antibodies and…”
Get full text

Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections by VAN WART, S. A, OWEN, J. S, LUDWIG, E. A, MEAGHER, A. K, KORTH-BRADLEY, J. M, CIRINCIONE, B. B

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem by BHAVNANI, Sujata M, HAMMEL, Jeffrey P, CIRINCIONE, Brenda B, WIKLER, Matthew A, AMBROSE, Paul G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects by Ellero, C., Han, J., Bhavsar, S., Cirincione, B. B., DeYoung, M. B., Gray, A. L., Yushmanova, I., Anderson, P. W.

“…Diabet. Med. 27, 1168–1173 (2010) Aims  Transient nausea and, to a lesser extent, vomiting are common adverse effects of exenatide that can be mitigated by…”
Get full text

Gatifloxacin and the elderly: pharmacokinetic–pharmacodynamic rationale for a potential age-related dose reduction by Ambrose, Paul G., Bhavnani, Sujata M., Cirincione, Brenda B., Piedmonte, Marion, Grasela, Thaddeus H.

“…Objectives: Recently, anecdotal reports via the FDA’s MedWatch reporting system have documented rare but serious hyperglycaemia in elderly patients receiving…”
Get full text

Impact of HIV-1 tat protein on methamphetamine-induced inhibition of vesicular monoamine transporter2-mediated dopamine transport and methamphetamine conditioned place preference in HIV-1 tat transgenic mice by Zhu, Jun, Cirincione, Abagail B., Strauss, Matthew J., Davis, Sarah E., Eans, Shainnel O., Tribbitt, Danielle K., Alshakhshir, Nadine, McLaughlin, Jay P.

“…Perturbation of dopamine transmission has been implicated as a contributing factor in HIV-1 associated neurocognitive disorders with concurrent methamphetamine…”
Get full text

Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci by Ambrose, Paul G, Meagher, Alison K, Passarell, Julie A, Van Wart, Scott A, Cirincione, Brenda B, Bhavnani, Sujata M, Ellis-Grosse, Evelyn

“…Abstract Correctly determined susceptibility breakpoints are important to both the individual patient and to society at large. A previously derived patient…”
Get full text

Population Pharmacokinetics of Tigecycline in Healthy Volunteers by Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Owen, J. S.

“…Tigecycline, a novel glycylcycline, possesses broad‐spectrum antimicrobial activity. A structural population pharmacokinetic model for tigecycline was…”
Get full text

Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints by Ambrose, Paul G, Meagher, Alison K, Passarell, Julie A, Wart, Scott A. Van, Cirincione, Brenda B, Rubino, Chris M, Korth-Bradley, Joan M, Babinchak, Timothy, Ellis-Grosse, Evelyn

“…Abstract Potential tigecycline-Enterobacteriaceae susceptibility breakpoints were evaluated using 2 approaches, which differed in the nature of the…”
Get full text

Challenges in the transition to model-based development by Grasela, Thaddeus H, Fiedler-Kelly, Jill, Walawander, Cynthia A, Owen, Joel S, Cirincione, Brenda B, Reitz, Kathleen E, Ludwig, Elizabeth A, Passarell, Julie A, Dement, Charles W

“…Practitioners of the art and science of pharmacometrics are well aware of the considerable effort required to successfully complete modeling and simulation…”
Get full text

PO43 - Les anticorps anti-exénatide ne réagissent ni avec le GLP-1 humain, ni avec le glucagon et n’altèrent ni l’efficacité, ni la sécurité d’un traitement par exénatide by Fineman, M, Mace, K, Diamant, M, Salaun-Martin, C, Darsow, T, Cirincione, B, Porter, B, Trautmann, M

“…Introduction Les peptides pharmaceutiques étant immunogéniques, les patients traités par exénatide peuvent développer des anticorps anti-exénatide (ACexe). La…”
Get full text

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects by Darpö, Börje, Philip, Sager, MacConell, Leigh, Cirincione, Brenda, Mitchell, Malcolm, Han, Jenny, Huang, Wenying, Malloy, Jaret, Schulteis, Christine, Shen, Larry, Porter, Lisa

“…Aims Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QTc) at…”
Get full text

PIII-10Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects by VANWART, S, CIRINCIONE, B, LUDWIG, E, CHEN, X, SHOAF, S, GRASELA, T, MALLIKAARJUN, S

Get full text

OI-A-1Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP) by VANWART, S, CIRINCIONE, B, LUDWIG, E, CHEN, X, SHOAF, S, GRASELA, T, MALLIKAARJUN, S

Get full text

OI-A-1 by Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Chen, X., Shoaf, S., Grasela, T. H., Mallikaarjun, S.

“…AIM TOL is a oral vasopressin (V2) receptor antagonist under development for treatment of CHF and/or HYP. Direct and indirect effect PK/PD models were…”
Get full text

PIII-10 by Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Chen, X., Shoaf, S., Grasela, T. H., Mallikaarjun, S.

“…AIM Direct effect, indirect effect, and competitive antagonism models were evaluated to describe plasma TOL concentration (Cp) effect on urine flow rate (UFR),…”
Get full text